Skip to main content
Premium Trial:

Request an Annual Quote

Geneva Bioinformatics, Swiss Institute of Bioinformatics, AnaSpec

Premium
Geneva Bioinformatics and the Swiss Institute of Bioinformatics this week released the commercial version of Aldente, a peptide mass fingerprint tool developed by SIB’s Proteome Informatics Group. The enhanced version builds upon the existing free version of Aldente released in 2002.
 
The new version allows researchers to use the software locally, giving them the ability to upload their proprietary sequence databases in a secured environment; perform batch submission; and access results and graphically evaluate them in detail and export them in different formats.
 

 
AnaSpec last week introduced 32 new peptides for drug discovery research, including beta-amyloid A4 protein precursor; M1128, viral matrix protein; and obestatin. The company also launched three new anti-LC antibodies: Anti-MAP1-LC3 alpha (NT; Anti-MAP1-LC3 beta (NT); and Anti-MAP1-LC3 alpha/beta (IN)

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.